Phase 3 Clinical Trials With Primary Completion Dates in May 2020

This is a list of Phase 3 trials with primary completion dates in May 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
BTAI BioXcel Therapeutics, Inc. 2020-05-01 Phase 3 NCT04268303 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
BVXV BiondVax Pharmaceuticals Ltd. 2020-05-01 Phase 3 NCT03450915 A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
BYSI BeyondSpring Inc. 2020-05-01 Phase 3 NCT02504489 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
ITCI Intra-Cellular Therapies, Inc. 2020-05-01 Phase 3 NCT02600507 Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
LXRX Lexicon Pharmaceuticals, Inc. 2020-05-01 Phase 3 NCT03521934 Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
MIRM Mirum Pharmaceuticals, Inc. 2020-05-01 Phase 3 NCT03905330 A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
MMSI Merit Medical Systems, Inc. 2020-05-01 Phase 3 NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
OTIC Otonomy, Inc. 2020-05-01 Phase 3 NCT03664674 Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
RETA Reata Pharmaceuticals, Inc. 2020-05-01 Phase 3 NCT02657356 Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
SAGE Sage Therapeutics, Inc. 2020-05-01 Phase 3 NCT03771664 A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia
SLNO Soleno Therapeutics, Inc. 2020-05-01 Phase 3 NCT03440814 A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
SPRO Spero Therapeutics, Inc. 2020-05-01 Phase 3 NCT03788967 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
ZEAL Zealand Pharma A/S 2020-05-01 Phase 3 NCT03777176 Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism